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1. Introduction
Kidney transplantation is the preferred therapy for most patients with end-stage renal disease.
The demand for kidney grafts however far exceeds the supply of available organs. As a result,
transplant teams increasingly use organs from extended criteria donors, of older age or with
significant comorbidity. This use of extended criteria organs is not without consequences.
Older donor age is strongly related to impaired kidney graft function and graft failure because
older kidneys are limited in their capacity to tolerate injury [1]. Aging is associated with renal
structural changes en functional decline. Older kidneys lose renal parenchyma and trough this
have a decreased renal plasma flow and tubular dysfunction. The mechanisms required for
tissue repair after damage become less reliable, resulting in a decrease in repair capacity. This
functional decline in the potential to repair and regenerate is often considered a hallmark of
the aging phenotype [2] [3].
Another major component of the aging phenotype is replicative or cellular senescence, which
is defined as permanent, irreversible growth arrest. In this chapter we draw the parallel
between the aging kidney in the transplantation setting and cellular senescence.
2. Impact of older donor age on transplantation outcome
The success of organ transplantation in patients with end-stage renal damage gave rise to
waiting lists and organ shortage. This in itself led to the increasing use of kidneys from older
or expanded criteria donors for transplantation. In 2002 the term Expanded criteria donor
(ECD) was codified to be deceased donors aged 60 years of older and those aged 50-59 years
with at least 2 of the following characteristics: history of hypertension, serum creatinine level
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greater than 1.5 mg/dL and cerebrovascular cause of death. The risk of graft failure after an
ECD kidney transplant is 70% higher than after a non- ECDtransplant [4].
Also Ojo et al. have reported on the survival of recipients of marginal kidneys, defined as
kidneys with one or more of the following pretransplant factors: donor age >55 years, non-
heartbeating donor, cold ischemia time >36 h, and donor hypertension or diabetes mellitus of
>10 years duration. Also in this study, marginal kidney transplants had a lower allograft
outcomes compared with organs from ideal donors [5].
In another study, Woo et al. compared two groups only divided by age. There was a larger increase
in graft failure rates of kidneys from donors >55 years of age. Also the mean estimated glomeru‐
lar filtration rate 6 months post-transplant and the stability of the glomerular filtration rate in the
first transplant year were significantly higher in the recipients of donors <55 years [6].
Recent data on 1063 kidney grafts from living donors confirm the association between older
donor age and graft outcome even after living donation, where living donors are screened
prior to transplantation and comorbidities are avoided. Increasing living donor age was
associated with lower kidney function after transplantation, loss of glomerular filtration rate
beyond 1 year and reduced graft survival [7].
With the increasing use of older and extended criteria donor kidneys, the intrinsic quality of
the kidneys at transplantation is nowadays much more important for the post-transplant
histological evolution and long-term graft survival than acute T-cell mediated rejection [1, 8,
9]. The causes by which older kidneys lose function after transplantation remain however
incompletely understood. This may involve both early and late-onset processes and is likely
to be found mainly in a significant effect of donor age on the subclinical progression of chronic
histological damage [10]. In a large study using protocol biopsies, it was not only demonstrated
that higher donor age is the major determinant of this non-specific chronic allograft damage,
but also that the association between donor age and post-transplant histological damage is
independent of the histological quality of the graft at implantation [11]. This suggests that
donor age and the aging process in itself are playing an independent role on renal allograft
histological progression and long-term outcome. From these studies, it can even be hypothe‐
sized that the aging process in itself is accelerated after transplantation, and contributes to
transplant outcome [10].
3. Mechanisms of renal aging
It is essential to distinguish aging from age-related disease. Aging itself is not a disease but
seems to be the greatest risk factor for age-related pathology [12]. The altered molecules with
aging involve many different pathways, including cell integrity, cellular proliferation, cell
transport and energy metabolism. Many of these molecules and processes are not unique to
aging and are likely general pathways involved in tissue damage and repair. Aging is a
programmed biological process that is associated with small transcriptional differences in
many genes, rather than large expression changes in a small number of genes [13-16].
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The aging phenotype is the consequence of cellular senescence, of increased susceptibility to
apoptosis with older age, of impaired regeneration and repair, of decreased functional capacity
of stem cells and progenitor cells, of changes in the expression of growth factors with increasing
age, of mitochondrial changes, of dysregulation of autoregulatory pathways and of immune
system alterations and different immunogenicity of older tissue.
Of the previously mentioned mechanisms of aging, cellular senescence is classically seen as
one of the most important drivers of the aging process. Cellular senescence leads to permanent
and irreversible growth arrest and was detected in seminal in vitro studies by Hayflick and
Moorhead [17, 18]. Senescent cells remain viable but show a changed morphology, greater
heterogeneity, expression of SA-β-gal, accumulation of lipofuscin granules and lack of
response to mitogenic stimuli.
Cellular senescence is a specific response of mitotically active cells to various stressors. It is
determined by multiple factors, including the genetic regulation of metabolism, time, the
number cell cycles of replication, and most importantly the answer to injury and stress [11,
19]. Examples of these different factors are telomere shortening and telomere dysfunction, non-
telomere DNA damage (e.g. due to X-rays, oxidative stress and UV irradiation), mitogenic
signals including those produces by oncogens (wich also cause DNA damage) and non-
genotoxic stress like chromatin perturbation (epigenetic changes) and other stress factors [20,
21] (. Cellular senescence thus not only comprises exhaustion of a predetermined proliferative
capacity (intrinsic senescence or replicative senescence), but can also be induced by extrinsic
factors (stress-induced premature senescence).
In this light, the impact of cellular senescence goes beyond the importance for aging. Cellular
senescence pathways play essential roles in tumor suppression, tumor promotion and tissue
repair.
There is increasing evidence that cellular senescence is a tumor suppressive system (by
inducing growth arrest) and a tumor-promoting phenomenon (by secretion of inflammatory
cytokines) [22]. To reconcile the apparently conflicting impact of cellular senescence on cancer,
Campisi et al. suggest that cellular senescence is a biological process that was selected to
promote fitness in young organisms (beneficial: tumor suppression, tissue regeneration), but
is deleterious in old organisms (harming: aging, tumor promotion) [23]. In the evolution,
senescence pathways evolved in an environment where organism lifespan was short. There‐
fore tumor-suppressor mechanisms needed to be effective for only a relatively short (repro‐
ductive) period [21]. Even if this mechanism was harmful later on, this would not affect
selective pressure. This concept is the essence of the “antagonistic pleiotropy hypothesis” and
makes us understand the senescence concept much better [23].
4. The replicative senescence pathways in renal disease and transplantation
Replicative senescence depends mainly on two pathways: the ARF-p53-p21 signaling pathway
that is partially telomere dependent and the p16-pRb pathway, which is independent of
telomere dysfunction. These pathways interact but can act independently [21, 24].
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1. Replicative senescence pathways ARF-p53-p21 (associated with telomere shortening).
Telomeres comprise tandem TTAGGG repeats of 5000 to 15000 base pairs that normally reside
at the ends of chromosome ends as protection and prevent end-to-end fusion of chromosomes.
Telomeric DNA is synthesized and its length is regulated by telomerase. Most somatic cells
don’t express telomerase and mature telomeres tend to progressively shorten with every cell
division. The crucial role of telomerase absence in the telomere shortening is proven in vitro
as telomere shortening can be bypassed by transfection with telomerase [25].
Telomere length reflects several important factors such as heredity, telomerase activity, the
efficiency of telomere-binding proteins, the rate of cellular proliferation and oxidative stress
in the milieu. Although telomere length is partly heritable, there are major differences in
telomere length even among monozygotic twins, which suggests that environmental factors
(e.g. hyperglycemie, oxidative stress [26, 27]) play a major role in telomere attrition and aging.
When the telomeres become critically short (reach the “Hayflick limit”) a classical DNA-
damage response is triggered with participation of several protein kinases (e.g. ATM and
CHK2), adaptor proteins (e.g. 53BP1 and MDC1) and chromatin modifiers (e.g. gammaH2AX).
Telomere shortening also leads to activation of the p53 pathway (trough p53 phosphorylation)
and herewith associated p21 (also termed CDKN1a, p21Cip1, Waf1 or SD11) expression. Also
other DNA damage responses (DDRs) and ARF (alternate reading frame, p14) can lead to
activation of the p53 pathway. SIRT1 (sirtuin 1) can negatively regulate p53 localization to the
nucleus and its function as a transcription factor.
The clinical importance of telomere shortening has been suggested in a very interesting study,
where leukocyte telomere length was used as a biomarker of aging. In this study, the associ‐
ation between telomere length and various disease processes was independent of chronolog‐
ical age, which suggests the value of telomere length measurement as a biomarker of biological
or cellular age [28].
In contrast to, e.g. blood cells, the association between age and telomere shortening in renal
tissue was only studied scarcely. The supposed association with reduced regenerative capacity
during aging and chronic diseases, and after acute injury, seems valid but has never been
proven in humans. Only Westhoff ‘s study in telomerase deficient mice suggests that critical
telomere shortening in kidneys leads to increased senescence and apoptosis, thereby limiting
regenerative capacity [29].
In adult kidneys, telomerase activity is very low, which results in telomere shortening by every
cell division, as was demonstrated by Melk et al [25].. Also ischemia can induce telomere
shortening as has been shown in different animal models [30-32] Finally, glomerular diseases
like IgA nephropathy, lupus nephritis and focal glomerulosclerosis are associated with
increased p53 expression compared to kidneys without lesions, both in animals [33] and in
humans [34, 35] Whether this relates to telomere length has not been studied to date.
After bone marrow transplantation telomere shortening occurs significantly more rapidly than
would be expected in graft-derived leukocytes. Probably due to the replicative stress on the
blood cell caused the kinetics of haemopoietic engraftment [36]. After solid organ transplan‐
tation there are arguments to state that transplantation is associated with accelerated short‐
ening of telomere length in the transplanted cells [12]. In transplanted renal cells, there is
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evidence for an increased cell turnover at the time of transplantation and a phase of increased
cell regeneration directly after transplantation that correlates with cold ischemia time [37, 38].
Also a small study showed that shorter telomere length in biopsies obtained at implantation
was associated with lower graft function at 12 months after transplantation, but no correlation
with p21 or p53 was found [39]. These studies need further validation to confirm the role of
telomere shortening on transplant outcome.
2. p16-pRB pathways (independent of telomere dysfunction).
DNA damage by environmental stress is the main stressor for activation of the p16-pRB
pathway although dysfunctional telomeres can also induce p16 [21]. This telomere-independ‐
ent senescence pathway is currently often referred to as ‘STATIS’ (Stress and Aberrant
Signaling-Induced Senescence. P16 (encoded by CDKN2A) is an important tumor suppressor
in the p53 pathway. P16 keeps pRB in an active hypophosphorylated form, which inhibits cell
proliferation and induces growth arrest [12]. The p53 and p16-pRB pathways interact witch
each other and there is a reciprocal regulation.
In native kidneys increased p16 expression is found in human kidneys with glomerular disease
[16], interstitial fibrosis, diabetic nefropathy [40] and animal kidneys with hypertension [41].
Furthermore p16 is induced by cyclosporine, catch up growth in low birth weight and is
attenuated by calorie restriction [12]. Finally, p16 expression correlates significantly with
kidney age [42].
Like the p53 pathway p16 expression relates to ischemia-reperfusion, at least in mice [43].
Furthermore, a rapid increase in p16 expression after transplantation has been described in
murine kidney grafts, which was most pronounced in older animals. Whether these findings
are also valid in humans, remains unknown.
5. Summary
In summary, there is extensive data that the outcome of kidney transplantation is heavily
influenced by the age of the transplanted kidneys. There is some scant evidence that trans‐
plantation in itself increases cell turnover and leads to accelerate replicative senescence.
Whether the association between older kidneys and impaired graft outcome relates to this
accelerate replicative senescence after transplantation is however not clear, and the few
suggestions in the literature need to be validated in large-enough patient cohorts.
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